CSL.AX - CSL Limited

ASX - ASX Delayed price. Currency in AUD
-0.94 (-0.33%)
At close: 4:10PM AEST
Stock chart is not supported by your current browser
Previous close282.37
Bid310.10 x 0
Ask253.72 x 0
Day's range280.42 - 284.97
52-week range215.24 - 342.75
Avg. volume1,108,689
Market cap127.733B
Beta (5Y monthly)0.26
PE ratio (TTM)63.72
Earnings dateN/A
Forward dividend & yield2.93 (1.04%)
Ex-dividend date11 Mar 2020
1y target estN/A
Press releases
  • GlobeNewswire

    uniQure Announces License Agreement with CSL Behring to Commercialize Hemophilia B Gene Therapy

    LEXINGTON, Mass. and AMSTERDAM, June 24, 2020 (GLOBE NEWSWIRE) -- uniQure N.V. (QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical needs, today announced that uniQure and CSL Behring have entered into a licensing agreement providing CSL Behring with exclusive global rights to etranacogene dezaparvovec, uniQure’s investigational gene therapy for patients with hemophilia B. Etranacogene dezaparvovec consists of an AAV5 viral vector carrying a gene cassette with the patent-protected Padua variant of Factor IX (FIX-Padua). Under the terms of the agreement, uniQure will receive a $450 million upfront cash payment and be eligible to receive up to $1.6 billion in payments based on regulatory and commercial milestones.